Chris LeMasters is the Executive Chairman of the Board for Khartis Therapeutics and Venture Partner at Foresite.  Chris led the business development process for Chimagen's sale of its lead asset to GSK. Chris most recently was the Chief Executive Officer of XinThera, where he was responsible for the company’s strategic, financial, and operational functions which led to the successful sale to Gilead in 2023.  Prior to XinThera, he was COO of Amplyx Pharmaceuticals, where he led the strategic efforts that resulted in the company’s successful sale to Pfizer in April 2021.  Chris was previously EVP & CBO of Mirati Therapeutics and the CEO of Promosome, a privately held mRNA re-engineering company co-founded by Nobel Laureate Dr. Gerald M. Edelman.  Over his 30+ year career, Chris has co-founded and served as a management team member for multiple biotechnology companies, including Cabrellis Pharmaceuticals (acquired by Pharmion), Conforma Therapeutics (acquired by Biogen IDEC), Tragara Pharmaceuticals (acquired by Cothera), and Aarden Pharmaceuticals.